BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26562161)

  • 1. Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
    Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
    PLoS One; 2015; 10(11):e0142310. PubMed ID: 26562161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
    Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi AR; Hadavi R; Österborg A; Shokri F; Rabbani H; Mellstedt H
    Leukemia; 2012 Jun; 26(6):1348-55. PubMed ID: 22289919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.
    Daneshmanesh AH; Mikaelsson E; Jeddi-Tehrani M; Bayat AA; Ghods R; Ostadkarampour M; Akhondi M; Lagercrantz S; Larsson C; Osterborg A; Shokri F; Mellstedt H; Rabbani H
    Int J Cancer; 2008 Sep; 123(5):1190-5. PubMed ID: 18546292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination of TLR7 agonist T7-ethacrynic acid conjugate with ROR1 has a stronger anti-breast cancer effect].
    Zhang N; Jin G; Jin Z; Liu B; Peng B; Gao N; Hu Y; Tang L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jul; 32(7):876-80. PubMed ID: 27363264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL).
    Uhrmacher S; Schmidt C; Erdfelder F; Poll-Wolbeck SJ; Gehrke I; Hallek M; Kreuzer KA
    Leuk Res; 2011 Oct; 35(10):1360-6. PubMed ID: 21531460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
    Hudecek M; Schmitt TM; Baskar S; Lupo-Stanghellini MT; Nishida T; Yamamoto TN; Bleakley M; Turtle CJ; Chang WC; Greisman HA; Wood B; Maloney DG; Jensen MC; Rader C; Riddell SR
    Blood; 2010 Nov; 116(22):4532-41. PubMed ID: 20702778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
    Baskar S; Kwong KY; Hofer T; Levy JM; Kennedy MG; Lee E; Staudt LM; Wilson WH; Wiestner A; Rader C
    Clin Cancer Res; 2008 Jan; 14(2):396-404. PubMed ID: 18223214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.
    Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
    PLoS One; 2013; 8(10):e78339. PubMed ID: 24205204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.
    Choi MY; Widhopf GF; Wu CC; Cui B; Lao F; Sadarangani A; Cavagnaro J; Prussak C; Carson DA; Jamieson C; Kipps TJ
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S167-9. PubMed ID: 26297272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.
    Fukuda T; Chen L; Endo T; Tang L; Lu D; Castro JE; Widhopf GF; Rassenti LZ; Cantwell MJ; Prussak CE; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3047-52. PubMed ID: 18287027
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
    Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
    Yang J; Baskar S; Kwong KY; Kennedy MG; Wiestner A; Rader C
    PLoS One; 2011; 6(6):e21018. PubMed ID: 21698301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.
    Deniger DC; Yu J; Huls MH; Figliola MJ; Mi T; Maiti SN; Widhopf GF; Hurton LV; Thokala R; Singh H; Olivares S; Champlin RE; Wierda WG; Kipps TJ; Cooper LJ
    PLoS One; 2015; 10(6):e0128151. PubMed ID: 26030772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
    Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
    Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
    Hasan MK; Yu J; Chen L; Cui B; Widhopf Ii GF; Rassenti L; Shen Z; Briggs SP; Kipps TJ
    Leukemia; 2017 Dec; 31(12):2615-2622. PubMed ID: 28465529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-translational modifications regulate signalling by Ror1.
    Kaucká M; Krejčí P; Plevová K; Pavlová S; Procházková J; Janovská P; Valnohová J; Kozubík A; Pospíšilová S; Bryja V
    Acta Physiol (Oxf); 2011 Nov; 203(3):351-62. PubMed ID: 21481194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative and Apoptotic Effects of Novel Anti-ROR1 Single-Chain Antibodies in Hematological Malignancies.
    Aghebati-Maleki L; Younesi V; Baradaran B; Abdolalizadeh J; Motallebnezhad M; Nickho H; Shanehbandi D; Majidi J; Yousefi M
    SLAS Discov; 2017 Apr; 22(4):408-417. PubMed ID: 28328317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.
    Li P; Harris D; Liu Z; Liu J; Keating M; Estrov Z
    PLoS One; 2010 Jul; 5(7):e11859. PubMed ID: 20686606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.